Filing Flows › Health Care › Neonc Technologies Holdings (NTHI)
Neonc Technologies Holdings (NTHI) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 9, 2025 · Neonc Technologies Holdings (NTHI) Q1 2025 earnings results →
Q1 2025 Revenue down 7% year over year to $40K
Neonc Technologies Holdings made $40K in Q1 2025 (-7% Y/Y). Operating margin n/m, net loss $38.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 9, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $40K in Q1 2025, down 7% year over year and up 100% from the previous quarter.
Operating costs exceeded revenue by $37.6M, an operating margin of -93965.5%. Total costs grew 2259% against a revenue fall of 7%. The fastest-growing cost line was Other operating costs (+4230%). The quarter ended with a net loss of $38.0M, wider than the previous quarter's $2.3M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $23.1M of share-based compensation. Working capital and other items added $9.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 9, 2025 | $40K | -7% | n/m | −$38.0M | −$5.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Neonc Technologies Holdings
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain- malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy.
In its own words, from its 10-K, filed Mar 31, 2026.
Neonc Technologies Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -7% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NTHI Neonc Technologies Holdings | Q1 2025 | $40K | -7% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Neonc Technologies Holdings 10-Q on SEC EDGAR · CIK 1979414 · Pharmaceutical Preparations
13F: who owns NTHI and who is buying
More on NTHI
History
Every quarter: Q1 2025 results